Search

Search Constraints

You searched for: Author/Creator Le, X.

Search Results

2. First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET. (October 2020)

3. Overexpression of the polarity protein PAR‐3 in clear cell renal cell carcinoma is associated with poor prognosis. Issue 9 (7th November 2013)

4. Preliminary interim data of elzovantinib (TPX-0022), a novel inhibitor of MET/SRC/CSF1R, in patients with advanced solid tumors harboring genetic alterations in MET: Update from the Phase 1 SHIELD-1 trial. (October 2022)

5. The Phase-I trigger readout electronics upgrade of the ATLAS Liquid Argon calorimeters. (1st May 2022)